A single-oral bolus of 100, of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Vitamin D status has been implicated in COVID-19 disease.

In the same cohort, the association between baseline serum calcidiol levels with the same outcomes was also analysed.

Who Took Part

Patients older than 18 years with moderate-severe COVID-19 disease requiring hospitalisation were included.

At admission, patients were randomised 1:1 to receive a single oral bolus of cholecalciferol (n=274) or nothing (n=269).

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label and multicenter study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

The COVID-VIT-D is a multicentre, international, randomised, open label, clinical trial conducted throughout 1 year.

Length of hospitalisation, admission to intensive care unit (ICU) and mortality were assessed.

What Was Measured

In the same cohort, the association between baseline serum calcidiol levels with the same outcomes was also analysed.

PubMed files the paper under topics including COVID-19, Cholecalciferol, Hospitalization, Hospitals, SARS-CoV-2 and Vitamin D.

The authors tagged it with the keywords COVID-19 disease.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (BMC medicine), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.